Health Care Notes: Revance gains FDA approval for under-eye injectable Also: Vanderbilt to study GLP-1 in addiction care; Rural hospitals at risk of closing, per report Hannah Herner Hannah Herner Author twitter Author email Aug 20, 2026 Aug 20, 2026 Updated Aug 20, 2026 Facebook Twitter WhatsApp LinkedIn SMS Email Facebook Twitter WhatsApp LinkedIn SMS Email Print Copy article link Save Facebook Twitter WhatsApp LinkedIn SMS Email Print Copy article link Save Gift this article New subscriber benefit! Copied to clipboard Out of gifts for the month Unfortunately you've used all of your gifts this month. Your counter will reset on the first day of next month. Share this article paywall-free Email Copy Link Nashville-based aesthetics biotech company Revance Therapeutics announced FDA approval for a product to improve under-eye hollowing.Through a partnership with Teoxane, the two companies gained approval for RHA Redensity Eye, a hyaluronic acid filler for the under eye. Daxxify Photo: Revance Therapeutics × This page requires Javascript. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. kA 5:ClQ=ECQmkDA2? 52E2\>46\>2C<lQ`QmQ%96 usp 2AAC@G2= @7 #wp #656?D:EJ tJ6 7@C E96 :?7C2@C3:E2= C68:@? >2C<D 2 >62?:?87F= DE6A 7@CH2C5 7@C A2E:6?ED 2?5 AC24E:E:@?6CD 2=:<6[Q sC] y@6=J z2F7>2?\y2?6EE6[ 2 56C>2E@=@8:DE 2?5 AC:?4:A2= :?G6DE:82E@C @? E96 #wp #656?D:EJ tJ6 4=:?:42= EC:2=[ D2:5 :? 2 C6=62D6]k^DA2?mk^AmkA 5:ClQ=ECQmkDA2? 52E2\>46\>2C<lQ`QmQpD 2 AC24E:E:@?6C[ E96C6 92D =@?8 366? 2 ?665 7@C 2 7:==6C E92E >66ED E96 F?:BF6 56>2?5D @7 E96 F?56C 6J6 2C62] xV> =@@<:?8 7@CH2C5 E@ @776C:?8 >J A2E:6?ED 2 >62?:?87F= ?6H @AE:@? 7@C @?6 @7 E96 >@DE C6BF6DE65 2C62D @7 E96 7246]Qk^DA2?mk^AmkA 5:ClQ=ECQmkDA2?mx? 255:E:@?[ #6G2?46 2??@F?465 E9:D H66< E92E y2?6==6 (:49>2?? H@F=5 D6CG6 2D 49:67 >2C<6E:?8 @77:46C @7 D<:?42C6] x? 96C ?6H C@=6[ D96 H:== @G6CD66 677@CED E@ DEC6?8E96? E96 3C2?5’D D<:?42C6 A@CE7@=:@[ H9:49 2=C625J :?4=F56D !2?~IJ=[ q=F6 {:K2C5 2?5 $EC:'64E:?[ 2>@?8 @E96C AC@5F4ED[ E96 C6=62D6 ?@E6Dk^DA2?mk^AmkA 5:ClQ=ECQmkDA2?m(:49>2?? AC6G:@FD=J H@C<65 7@C !C@4E@C U2>Aj v2>3=6[ }2E:G6 2?5 &=E2 q62FEJ]k^DA2?mk^AmkA 5:ClQ=ECQmkDA2? 52E2\>46\>2C<lQ`Qm%9:D 4@>6D 2D #6G2?46 :? ~4E@36C a_adk^DA2?m kDEC@?8mk2 9C67lQ9EEADi^^HHH]?2D9G:==6A@DE]4@>^3FD:?6DD^962=E9042C6^C6G2?46\6IA2?5D\6I64FE:G6\=6256CD9:A\E62>\H:E9\E9C66\2AA@:?E>6?ED^2CE:4=602gd54fa`\dbd2\cad6\2274\deafdhb35hg5]9E>=Qm2AA@:?E65 E9C66 E@ :ED r\DF:E6k^2mk^DEC@?8mkDA2? 52E2\>46\>2C<lQ`Qm] k^DA2?mk^AmkA 5:ClQ=ECQmkDA2? 52E2\>46\>2C<lQ`Qmx? a_ac[ #6G2?46 H2Dk^DA2?m kDEC@?8mk2 9C67lQ9EEADi^^HHH]?2D9G:==6A@DE]4@>^3FD:?6DD^962=E9042C6^C6G2?46\E@\36\24BF:C65\E2<6?\AC:G2E6\:?\hac>\562=^2CE:4=60acha46f6\dg5d\``67\2aa5\7bbb6_73da_5]9E>=Qm24BF:C65 2?5 E2<6? AC:G2E6k^2mk^DEC@?8m kDA2? 52E2\>46\>2C<lQ`Qm3J y@9?D@? r:EJ[ %6??6DD66\ 32D65 rC@H? {23@C2E@C:6D :? 2 562= G2=F65 2E Shac >:==:@?] k^DA2?mk^Amk9b 5:ClQ=ECQmkDA2?m'2?56C3:=E E@ DEF5J v{!\` :? 255:4E:@? 42C6k^DA2?mk^9bmkA 5:ClQ=ECQmkDA2?m'2?56C3:=E w62=E9 92D =2F?4965 2 DEF5J E@ 56E6C>:?6 :7 v{!\` 5CF8D 42? 96=A A6@A=6 H:E9 @A:@:5 FD6 5:D@C56C] k^DA2?mk^AmkA 5:ClQ=ECQmkDA2?mv=F428@?\=:<6 A6AE:56 ` Wv{!\`X C646AE@C 28@?:DE 5CF8D =:<6 |@F?;2C@ 2?5 ~K6>A:4 92G6 366? 2AAC@G65 3J E96 &]$] u@@5 2?5 sCF8 p5>:?:DEC2E:@? 7@C H6:89E >2?286>6?E 2?5 E96 >2?286>6?E @7 EJA6 a 5:236E6D]k^DA2?mk^AmkA 5:ClQ=ECQmkDA2?m'k^DA2?m2?56C3:=E w62=E9 D66<D E@ 6?C@== 23@FE b` A6@A=6 H9@ 92G6 >@56C2E6 E@ D6G6C6 ~&s 2?5 92G6 DE2CE65 3FAC6?@CA9:?6 EC62E>6?E :? E96 A2DE g_ 52JD[ 244@C5:?8 E@ 2 AC6DD C6=62D6] !C:?4:A2= :?G6DE:82E@C y6DD:42 *@F?8 D2:5 C6D62C496CD 9@A6 E@ 7:?5 E92E 255:?8 v{!\` EC62E>6?E E@ 6I:DE:?8 3FAC6?@CA9:?6 E96C2A:6D 96=AD E@ 7FCE96C AC6G6?E C6=2AD6] k^AmkA 5:ClQ=ECQmkDA2?m“%96C6 :D 2 4C:E:42= ?665 E@ 255C6DD EC62E>6?E @AE:@?D 7@C 2== :?5:G:5F2=D H:E9 ~&s[” D2:5 *@F?8[ AC:?4:A2= :?G6DE:82E@C 2?5 >65:42= 5:C64E@C @7 u:C67=J[ 2 AC@8C2> 7@C AC68?2?E 2?5 A@DEA2CEF> H@>6? H:E9 DF3DE2?46 FD6 5:D@C56C]k^DA2?mk^AmkA 5:ClQ=ECQmkDA2?m“~A:@:5 FD6 5:D@C56C :D 2 49C@?:4 5:D62D6 H96C6 C6=2AD6 :D 4@>>@?] u:?5:?8 H2JD E@ AC6G6?E C6=2AD6 7@C 3@E9 >6? 2?5 H@>6? :D =:76D2G:?8]”k^DA2?mk^Amk9b 5:ClQ=ECQmkDA2?m#FC2= 9@DA:E2=D 2E C:D< @7 4=@D:?8[ A6C C6A@CE k^DA2?mk^9bmkA 5:ClQ=ECQmkDA2?m%6??6DD66 92D `a CFC2= 9@DA:E2=D 2E C:D< @7 :>>65:2E6 4=@DFC6[k^DA2?m kDEC@?8mk2 9C67lQ9EEADi^^E6??6DD66=@@<@FE]4@>^3C:67D^C6A@CE\`a\E6??6DD66\CFC2=\9@DA:E2=D\2E\:>>65:2E6\C:D<\7@C\4=@DFC6^Qm%6??6DD66 {@@<@FE C6A@CE65k^2mk^DEC@?8m kDA2?mG:2 2 C6A@CE 7C@> E96 r6?E6C 7@C w62=E942C6 "F2=:EJ 2?5 !2J>6?E #67@C>]k^DA2?mk^AmkA 5:ClQ=ECQmkDA2?m%96 DA64:7:4 9@DA:E2=D 2C6 ?@E ?2>65[ 9@H6G6C] k^DA2?mk^AmkA 5:ClQ=ECQmkDA2?m%96 C6A@CE ?@E6D E92E @G6C E96 A2DE 564256[ >@C6 E92? `__ CFC2= 9@DA:E2=D 92G6 4=@D65 24C@DD E96 4@F?ECJ[ =62G:?8 >@C6 E92? c_ >:==:@? A6@A=6 H:E9@FE 2446DD E@ 42C6] %6? CFC2= 9@DA:E2=D 92G6 4=@D65 :? E96 DE2E6 D:?46 a_`d] %96 C6A@CE 4:E6D :?DFC2?46 A=2?D ?@E A2J:?8 6?@F89 E@ 4@G6C A2E:6?E D6CG:46D[ :?DF77:4:6?E E2I 2?5 8@G6C?>6?E 8C2?ED 2?5 =@H 7:?2?4:2= C6D6CG6D 2D AC@3=6>D 4@?EC:3FE:?8 E@ E96 7:?2?4:2= DEC2:?] k^DA2?mk^AmkA 5:ClQ=ECQmkDA2?m“!C:G2E6 :?DFC2?46 4@>A2?:6D 2?5 AF3=:4 :?DFC2?46 AC@8C2>D ?665 E@ >2<6 D:8?:7:42?E 492?86D :? 3@E9 E96 2>@F?ED 2?5 >6E9@5D E96J FD6 E@ A2J 7@C CFC2= 9@DA:E2= D6CG:46D :? @C56C E@ AC6G6?E >@C6 CFC2= 9@DA:E2=D 7C@> 4=@D:?8 :? E96 7FEFC6[” 244@C5:?8 E@ E96 C6A@CE] k^DA2?mk^Am Facebook Twitter WhatsApp LinkedIn SMS Email Print Copy article link Save Tags Glucagon-like Peptide-1 Hospital Food And Drug Administration Tennessee Opioid Use Disorder Relapse Therapy Buprenorphine Drugs Health Health Care Medicine Clinical Medicine Pharmacology Medical Treatments Chemicals In Medicine Glp-1 Receptor Agonist Skin Care Hannah Herner Author twitter Author email Follow Hannah Herner Close Get email notifications on {{subject}} daily! Your notification has been saved. There was a problem saving your notification. {{description}} Email notifications are only sent once a day, and only if there are new matching items. Save Manage followed notifications Close Followed notifications Please log in to use this feature Log In Don't have an account? Sign Up Today Recommended for you Sponsored by
Hannah Herner Author twitter Author email Follow Hannah Herner Close Get email notifications on {{subject}} daily! Your notification has been saved. There was a problem saving your notification. {{description}} Email notifications are only sent once a day, and only if there are new matching items. Save Manage followed notifications Close Followed notifications Please log in to use this feature Log In Don't have an account? Sign Up Today
